

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 67812

Title: Liver Transplantation For Pediatric Inherited Metabolic Liver Diseases

Reviewer's code: 03755068

Position: Peer Reviewer

Academic degree: MD

Professional title: Consultant Physician-Scientist

Reviewer's Country/Territory: Italy

Author's Country/Territory: United Kingdom

Manuscript submission date: 2021-05-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-04 16:12

Reviewer performed review: 2021-05-07 05:31

Review time: 2 Days and 13 Hours

| Scientific quality | [] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish |
|-----------------------------|--|
| Language quality | [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection |
| Re-review | [Y]Yes []No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |



SPECIFIC COMMENTS TO AUTHORS

This was a nice review on paediatric liver transplantation for inherited metabolic liver diseases. Although rare, these conditions represent increasing indications for liver transplantation in Centers with a Paediatric Liver Transplant Program. In my opinion, the Authors discussed several important topics, such as indications, contraindications to liver transplantation for each condition, and type(s) of transplant (Deceased-donor, domino, auxiliary, living-donor). More importantly, they addressed a very meaningful topic, such as the role of liver transplantation (as disease-curative event vs. life-improving event). This represents, in my opinion, an ethical issue, especially in the setting of paediatric liver transplant. References are appropriate. The paper is not redundant and is void of typos. Figures 1 and 3 are good, I would reconsider figure 2, explaining different types of available organ transplants (domino, deceased donor, living donor, auxiliary). Major comments: - Allogenic hepatocyte transplantations: are the available data on animal models or humans? - What medications can be used to increase nitrogen excretion in UCD? - Do patients with UCD improve their neurological damage after LT? - LT for WD: unfortunately, neurological improvement is not universal after transplant. This point may be added. - Patients with MMA: is simultaneous LKT encouraged ? are there available data about the long-term outcome of these patients? -GSD: the Authors said that adenomas can be considered indication to liver transplantation. Are there definite criteria (i.e., number, size, etc?) - Is chronic rejection more prevalent in LBMD than other paediatric indications? - Figure 1 is good; I would suggest to modify Figure 2 adding different types of liver transplantation (domino, split, auxiliary, living-donor). Figure 3: I suggest to add also graft survival. Minor comments: - typos: orlistat instead of orlistate; figure 1 haemocromatosis; bur-rage



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 67812

Title: Liver Transplantation For Pediatric Inherited Metabolic Liver Diseases

Reviewer's code: 03852265

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: United Kingdom

Manuscript submission date: 2021-05-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-10 03:32

Reviewer performed review: 2021-05-16 06:59

Review time: 6 Days and 3 Hours

| Scientific quality | [] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish |
|-----------------------------|---|
| Language quality | [Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection |
| Re-review | []Yes [Y]No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |



SPECIFIC COMMENTS TO AUTHORS

The manuscript is well written describing each characteristics of metabolic disease separately which contains brief summary of the disease, treatment, LTx and future possible therapies. I suggest that to make the manuscript better to understand easier for the readers, the authors may provide a table contains these separately described info together. Then, the manuscript will be ready for the publication.